drugset / Trial / NCT02941523
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Non-randomizedSingle-groupSingle-blindTreatment
Summary
The study evaluates the safety and activity of NOX66 in patients with refractory solid tumors that are non responsive to standard therapies. This is a two part with a potential third part, open-label, multicenter, dose escalation study of NOX66 as monotherapy and in combination with carboplatin.
Timeline
- Start
- 2017-03-03
- Primary completion
- 2018-12-31
- Completion
- 2019-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | NOX66 | Small molecule | 400 mg | — |
| Subject | NOX66 | Small molecule | 800 mg | — |